Iovance Biotherapeutics, Inc.
IOVA
$3.89
-$0.15-3.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 21.20% | 18.27% | 3.88% | -47.87% | 5.96% |
| Total Depreciation and Amortization | 8.28% | -2.19% | 7.89% | -35.53% | 69.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 48.70% | -59.25% | 21.27% | -39.68% | 18.02% |
| Change in Net Operating Assets | 14.53% | -192.85% | 152.13% | 59.43% | -253.16% |
| Cash from Operations | 33.21% | -16.69% | 34.96% | -41.47% | -24.29% |
| Capital Expenditure | 14.05% | -45.34% | -20.13% | -49.02% | -82.17% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -63.76% | 30.76% | -3.51% | -20.71% | 159.86% |
| Cash from Investing | -95.44% | 22.90% | -12.76% | -32.99% | 148.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -36.04% | 544.55% | -90.78% | 4,571.03% | -93.39% |
| Repurchase of Common Stock | 4.51% | 7.54% | 91.07% | -541.36% | 85.98% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -36.21% | 565.58% | -90.77% | 6,106.80% | -94.50% |
| Foreign Exchange rate Adjustments | 184.85% | -192.02% | 45.47% | 143.12% | -194.01% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -80.69% | 164.80% | -170.78% | 215.48% | 24.90% |